早期呼吸支持策略对危重型COVID-19疾病进展的影响:前瞻性RISC-19-ICU队列的匹配子分析
该研究为前瞻性多国注册队列RISC-19-ICU的子分析,按入ICU当天采用的呼吸支持策略将患者分为标准氧疗(SOT)、经鼻高流量氧疗(HFNC)、无创正压通气(NIV)和早期有创机械通气(IMV)四组,并进行倾向性评分匹配。匹配后共351例纳入分析(SOT 85例、HFNC 87例、NIV 87例、IMV 92例)。初始接受无创呼吸支持的患者中55%最终需要IMV;HFNC和NIV组插管率低于SOT组(SOT 64%、HFNC 52%、NIV 49%,p=0.025);NIV组总体ICU死亡率高于其他策略(SOT 18%、HFNC 20%、NIV 37%、IMV 25%,p=0.016)。作者认为HFNC是最平衡的初始策略,SOT和早期IMV是安全的初始策略,NIV应尽可能避免。
要点
- 初始接受无创呼吸支持的患者中55%最终需要有创机械通气。
- 插管率:SOT 64%、HFNC 52%、NIV 49%(p=0.025),HFNC和NIV低于SOT。
- ICU死亡率:SOT 18%、HFNC 20%、NIV 37%、IMV 25%(p=0.016),NIV组最高。
- 作者认为HFNC似乎是最平衡的初始呼吸支持策略:插管率降低且ICU死亡率相当。
- 作者认为SOT和早期IMV是安全的初始呼吸支持策略;NIV应尽可能避免,因ICU死亡风险升高。
适用人群与场景
- 危重型COVID-19成人患者,收入ICU时按当天采用的呼吸支持策略分组。
- 数据来自前瞻性多国注册队列RISC-19-ICU,评估时间为COVID-19大流行的最初数月。
处置流程与药物剂量
- 初始呼吸支持策略分为:标准氧疗≥10 L/min(SOT)、经鼻高流量氧疗(HFNC)、无创正压通气(NIV)、早期有创机械通气(IMV)。
- 作者认为HFNC似乎是初始呼吸支持最平衡的策略,因插管率降低且ICU死亡率相当。
- 作者认为SOT和早期IMV是安全的初始呼吸支持策略。
- 作者认为NIV应尽可能避免,因ICU死亡风险升高。
研究设计与关键结果
- 研究类型:前瞻性多国注册队列RISC-19-ICU的子分析,采用倾向性评分匹配保证组间可比性。
- 初始评估1421例患者,倾向性评分匹配后351例纳入全分析:SOT 85例、HFNC 87例、NIV 87例、IMV 92例。
- 初始接受无创呼吸支持的患者中55%需要有创机械通气。
- 插管率:SOT 64%、HFNC 52%、NIV 49%(p=0.025),HFNC和NIV低于SOT。
- 总体ICU死亡率:SOT 18%、HFNC 20%、NIV 37%、IMV 25%(p=0.016),NIV组高于其他呼吸支持策略。
证据类型、等级与局限
- 证据类型:前瞻性多国注册队列的子分析,采用倾向性评分匹配。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HFNC似乎是危重型COVID-19最平衡的初始呼吸支持策略:与SOT相比插管率降低(HFNC 52% vs SOT 64%),ICU死亡率相当(HFNC 20% vs SOT 18%)。
- 作者认为SOT和早期IMV是安全的初始呼吸支持策略。
- 作者认为NIV应尽可能避免,因ICU死亡风险升高(NIV 37% vs SOT 18%、HFNC 20%、IMV 25%)。
- 作者指出上述发现与经典ARDS文献一致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Uncertainty about the optimal respiratory support strategies in critically ill COVID-19 patients is widespread. While the risks and benefits of noninvasive techniques versus early invasive mechanical ventilation (IMV) are intensely debated, actual evidence is lacking. We sought to assess the risks and benefits of different respiratory support strategies, employed in intensive care units during the first months of the COVID-19 pandemic on intubation and intensive care unit (ICU) mortality rates.
METHODS: Subanalysis of a prospective, multinational registry of critically ill COVID-19 patients. Patients were subclassified into standard oxygen therapy ≥10 L/min (SOT), high-flow oxygen therapy (HFNC), noninvasive positive-pressure ventilation (NIV), and early IMV, according to the respiratory support strategy employed at the day of admission to ICU. Propensity score matching was performed to ensure comparability between groups.
RESULTS: Initially, 1421 patients were assessed for possible study inclusion. Of these, 351 patients (85 SOT, 87 HFNC, 87 NIV, and 92 IMV) remained eligible for full analysis after propensity score matching. 55% of patients initially receiving noninvasive respiratory support required IMV. The intubation rate was lower in patients initially ventilated with HFNC and NIV compared to those who received SOT (SOT: 64%, HFNC: 52%, NIV: 49%, p = 0.025). Compared to the other respiratory support strategies, NIV was associated with a higher overall ICU mortality (SOT: 18%, HFNC: 20%, NIV: 37%, IMV: 25%, p = 0.016).
CONCLUSION: In this cohort of critically ill patients with COVID-19, a trial of HFNC appeared to be the most balanced initial respiratory support strategy, given the reduced intubation rate and comparable ICU mortality rate. Nonetheless, considering the uncertainty and stress associated with the COVID-19 pandemic, SOT and early IMV represented safe initial respiratory support strategies. The presented findings, in agreement with classic ARDS literature, suggest that NIV should be avoided whenever possible due to the elevated ICU mortality risk.
参考来源
- Wendel Garcia PD, Aguirre-Bermeo H, Buehler PK, et al. Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort. Crit Care. 2021. PMID: 34034782. doi:10.1186/s13054-021-03580-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。